This is an early US Account Executive seat at a healthcare AI company building on-device documentation software for nurses — $150K base and $150K variable for a $300K OTE on a true 50/50 split, backed by a $50M Series A that includes Y Combinator. It is the third seller on the US team; two Account Executives started in August 2026, so nobody has ramped and nobody has closed in this market yet. The buyers are skilled nursing facility operators and large care chains, which means procurement-heavy enterprise cycles and real customer travel from a base near a major airport. New York is preferred but not required, and a first year here is judged more on pipeline built than revenue closed.
What is this Account Executive role, exactly?
It’s the third US seller at a healthcare AI company opening the American market, selling clinical documentation software built for nurses rather than physicians. The first wave of clinical AI documentation went to physicians. There are now hundreds of AI scribe products built for physician workflows, and that market is crowded and largely commoditized.
The nurse market looks completely different. Despite vastly larger headcount — nurses outnumber physicians several times over in the US — the AI scribe count for nurses is in the single digits. The buyers are different. The workflows are different. The technical requirements are different. That gap is not accidental; it’s structural.
Here’s the part that makes it a role worth talking about, and the reason I’m featuring it a second time. I placed one of the sellers who started in August. He called me unsolicited — not because anything was wrong, but to say thank you, that he loves the company, the product and the people, and to give me a heads-up that they need more people in the US. That is the most useful signal I get in this job, and it is not one I can manufacture.
Why hasn’t a physician scribe company just moved into nursing?
Because the existing stack can’t be retrofitted and the buyer relationships don’t transfer. Three things separate the two markets.
Documentation volume per shift. A physician generates roughly one substantive documentation entry per patient per visit. A nurse generates dozens to nearly a hundred — care plans, medication logs, vitals, observations, incident notes — across an entire shift. The product surface a physician scribe needs to cover and the product surface a nurse needs are different categories of software.
Connectivity constraints. Physicians document in offices, exam rooms and on hospital floors with reliable wifi. Nurses document inside patient rooms and care facilities, in environments where cloud-based AI structurally cannot run reliably. The AI has to be on-device, offline-capable, and sync when connection returns. Most physician-scribe architectures cannot retrofit to this. They’d have to rebuild.
Buyer composition. Physician scribes sell to medical practices, hospital systems and individual physicians. Nurse documentation sells to skilled nursing facility operators and large care chains — a different procurement profile, different ROI math, different sales cycle.
How does this compare to a typical founding Account Executive seat?
You get a proven product and an unproven territory, which is close to the inverse of a normal founding AE bet. The business underneath works — significant ARR in the home market, thousands of care facilities, hundreds of thousands of frontline users, hundreds of millions of records through the platform. What nobody knows yet is how fast the US converts. For the wider checklist, what good founding AE roles look like is the frame I use.
| Typical founding AE seat | This role | |
|---|---|---|
| Proof it works | Founder-led deals, often under $2M ARR | Significant ARR — in another market |
| Your risk | Product-market fit may not exist | Product is proven; US conversion is not |
| Base / OTE | $100K–$175K / $200K–$350K | $150K / $300K |
| Ramp | Often unguaranteed | Unguaranteed — budget for it |
| Peers | None — you are the first | Two AEs, weeks ahead at most |
| Year one judged on | Whatever the founder says on day one | Pipeline built more than revenue closed |
If you’re benchmarking the number against other offers, what a Founding Account Executive actually earns has the market ranges.
A weekly newsletter for founding AEs selling before the playbook exists.
Mostly the craft of the job; sometimes the career around it. Five minutes a week.
Where is the upside — and where is the risk?
The upside is that the US territory is genuinely open at a stage where opening it still counts for something; the risk is that early enterprise cycles are long and year one is judged on pipeline more than revenue. I want to be precise here, because this one is earlier than it looks.
Two sellers started in August 2026. In a procurement-heavy enterprise cycle, that means nobody has ramped and nobody has closed yet. You would not be inheriting a worn path; you’d be running roughly in parallel with two peers who are weeks ahead of you at most. That’s better than being the only rep in a new market, and it is not the same as a proven US motion.
What is proven is the business underneath: significant ARR in the company’s home market, thousands of care facilities, hundreds of thousands of frontline users, hundreds of millions of records through the platform. The product works at scale somewhere. The open question is how fast the US converts, and you would be one of the people answering it.
If you need a covered number in year one, this is the wrong seat. If you want a market to open, it’s a rare one.
Who is this role actually for?
An enterprise closer with five-plus years of B2B SaaS sales and a real track record on complex deals. A strong bias toward getting in front of customers, and a home base near a major airport — New York is preferred, not required. Comfortable building pipeline from scratch without heavy enablement or SDR support. Strong executive presence with experience in procurement-heavy environments. The moat is in selling complex software to non-software buyers.
Less obviously: this is an international company opening the US, and the go-to-market context largely sits overseas. You need to be an independent operator who is strong with ambiguity and able to translate what you’re seeing in the US market back to a leadership team that isn’t in the room.
What would I push on before signing?
One question above all: how the company defines a successful first year for a US seller, and whether that definition is pipeline or closed revenue. In a market this early, with cycles this long, the answer is the difference between a great seat and a frustrating one. It’s a fair question and a well-run company will have an answer.
My original view into this business came from working alongside the VP Global Sales. What I have now is better: a seller I placed, in the seat, who called me unprompted to tell me it’s good and that they need more people. He’s weeks in, so he’s telling me something real about the product, the founders and what he’s seeing in early conversations — not that the motion converts. Nobody knows that yet, and I’d rather say so.
The questions worth asking before you sign covers the rest of what I’d bring to a first call.
